Drug Safety Research Unit

Showing 1 posts of 1 posts found.


Remdesivir has a “favourable” benefit/risk profile in COVID-19 but more data needed, DSRU review argues

October 5, 2020
Research and Development, Sales and Marketing COVID-19, Drug Safety Research Unit, pharma, remdesivir

Southampton’s Drug Safety Research Unit (DSRU) has released a systematic benefit/risk analysis of Gilead’s antiviral drug remdesivir in the treatment …

Latest content